LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announced today that for the period of September 12, 2015 to March 11, 2016, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended September 9, 2015, in addition to the continued accrual of the original issue discount. Ziac (Biosoprolol - Hydrochlorothiazide) with no prescription Contingent cash interest, which the Company has determined to be approximately $1.98 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is February 25, 2016. Buy Betagan (Levobunolol) without prescription The payment of contingent cash interest is expected to be made on March 11, 2016. About LabCorp® Laboratory Corporation of America® Holdings, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. Buy Cozaar (Losartan) with free prescription LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people’s health by delivering the combination of world-class diagnostics, drug development and knowledge services. Febuxostat With combined revenue pro forma for the acquisition of Covance in excess of $8.5 billion in 2014 and more than 48,000 employees in over 60 countries, LabCorp offers innovative solutions to healthcare stakeholders. Buy Mellaril (Thioridazine) with free prescription LabCorp clients include physicians, patients and consumers, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and clinical labs. Buy Cascara Sagrada online To learn more about Covance Drug Development, visit .covance.com. http://webmd-help.blogspot.com To learn more about LabCorp and LabCorp Diagnostics, visit .labcorp.com. This press release contains forward-looking statements including with respect to estimated 2015 guidance and the impact of various factors on operating results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, adverse actions of governmental and other third-party payers and the results from the Company’s acquisition of Covance. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp’s operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2014, and the Company’s Form 10-Q for the quarter ended June 30, 2015, including in each case under the heading risk factors, and in the Company’s other filings with the SEC, as well as in the risk factors included in Covance’s filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2014, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Samenvatting ADC Therapeutics haalt 88 mln. dollar op voor antilichaam-medicijnverbindingen tegen kanker

. Buy Books online About Voveran (Diclofenac) without prescription LAUSANNE, Zwitserland & LONDEN & MURRAY HILL, N.J.--(BUSINESS WIRE)--Oncologisch bedrijf ADC Therapeutics, gespecialiseerd in gepatenteerde antilichaam-medicijnverbindingen (ADC’s) tegen veelvoorkomende kankersoorten, heeft vandaag bekendgemaakt dat het 80 miljoen dollar heeft opgehaald middels een onderhandse plaatsing. http://webmd-review.blogspot.com Estrofem with free Rx Vaseretic (Enalapril-Hydrochlorothiazide) without Rx Nieuwe geldschieters zijn onder meer grote Europese en Amerikaanse beleggers, die evenals oprichter Auven Therapeutics en AstraZeneca deelnemen aan de financieringsronde. ADC Therapeutics gebruikt de opbrengst voor de verdere ontwikkeling van zijn productportfolio, met onder meer ADCT-301 tegen maligne lymfoom en leukemie (momenteel in fase I) en een samenwerking met AstraZeneca’s onderzoeksfiliaal MedImmune aan twee commercieel levensvatbare ADC’s. Deze bekendmaking is officieel geldend in de originele brontaal. Ophthacare () with no prescription About Cialis Super Force (Tadalafil + Dapoxetine) with no prescription Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, welke als enige rechtsgeldig is.